Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

v3.5.0.2
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 5,906,000 $ 9,276,000
Accounts receivable 16,000 32,000
Prepaid expenses and other current assets 625,000 441,000
Mortgage note receivable, current portion 208,000 170,000
Total current assets 6,755,000 9,919,000
Property and equipment, net 320,000 430,000
Deposits 54,000 31,000
Mortgage note receivable, long-term portion 2,276,000 2,354,000
In process research and development 146,301,000 146,301,000
Goodwill 65,195,000 65,195,000
Total assets 220,901,000 224,230,000
Current liabilities:    
Accounts payable and accrued expenses 1,243,000 2,585,000
Derivative liabilities 1,907,000 4,115,000
Total current liabilities 3,150,000 6,700,000
Long-term liabilities    
Deferred rent 54,000 61,000
Deferred tax liability 49,875,000 49,875,000
Total long-term liabilities 49,929,000 49,936,000
Total liabilities 53,079,000 56,636,000
Stockholders' equity:    
Common stock, $.001 par value; 800,000 shares authorized; 714,032 and 694,396 issued and outstanding as of September 30, 2016 and December 31, 2015, respectively 714,000 694,000
Additional paid-in capital 238,784,000 229,456,000
Accumulated deficit (71,676,000) (62,556,000)
Total stockholders' equity 167,822,000 167,594,000
Total liabilities and stockholders' equity 220,901,000 224,230,000
Series A Convertible Preferred Stock    
Commitments and contingencies    
Series A convertible preferred stock, $0.001 par value; 1,000 shares authorized, 0 shares issued and outstanding at September 30, 2016 and December 31, 2015 respectively, issued in the merger with RFS Pharma, LLC
Stockholders' equity:    
Series B convertible preferred stock, $.001 par value; 5,000 shares authorized; 0 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively
Series B Convertible Preferred Stock    
Commitments and contingencies    
Series A convertible preferred stock, $0.001 par value; 1,000 shares authorized, 0 shares issued and outstanding at September 30, 2016 and December 31, 2015 respectively, issued in the merger with RFS Pharma, LLC
Stockholders' equity:    
Series B convertible preferred stock, $.001 par value; 5,000 shares authorized; 0 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively